Overview
- A multicentre study in The Lancet eClinicalMedicine found 83% of Indian patients in a sampled endoscopy cohort carried multidrug‑resistant organisms, far above rates reported in Italy, the US and the Netherlands.
- India unveiled NAP‑AMR 2.0 for 2025–29, a One Health strategy that assigns ministerial responsibilities, expands surveillance and laboratory capacity, strengthens infection control and tightens regulation of antimicrobial use.
- ECDC’s 2024 data show the EU/EEA reached the MRSA target but is off track for reducing third‑generation cephalosporin‑resistant E. coli and carbapenem‑resistant Klebsiella pneumoniae, with AMR estimated to cause over 35,000 deaths annually.
- WHO reporting reiterates that resistance is uneven globally, with the Southeast Asia and Eastern Mediterranean regions showing the highest shares, and projects severe long‑term health and economic impacts if trends continue.
- An industry‑sponsored European analysis reported falling prices for off‑patent antibiotics from 2020–2024 alongside rising production costs, market withdrawals and hundreds of shortages, raising risks to treatment availability.